...
首页> 外文期刊>Nutrition and Cancer: An International Journal >Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy
【24h】

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

机译:乳腺癌患者接受化疗的25-羟基乙多素D3循环水平的变化

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n?=?95), and a comparison group of women (n?=?52) not diagnosed with cancer. Changes in 25(OH)D3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in patients (estimated marginal mean 55.8?nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2?nmol/L, 95%CI 61.1–73.3, P?=?0.003). Directly after chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1?nmol/L, 95%CI –10.7–0.5, P?=?0.082), but ended up higher 6 months after chemotherapy (10.9?nmol/L, 95%CI 5.5–16.4, P?
机译:癌症治疗,毒性及其对生活方式的影响,可能会影响维生素D的水平。本研究的目的是在乳腺癌中化疗后直接和6个月内直接测定血清25-羟基维生素D3(25(OH)D3)水平患者(n?=α95),以及未被诊断出癌症的女性的比较组(n?=?52)。使用针对年龄和血液采样季节调整的线性混合模型进行比较25(OH)D3水平随时间的变化。在化疗开始之前,与比较组相比95%CI 61.1-73.3,P?= 0.003)。化疗后,25(OH)D3水平略微降低(-5.1 = Nmol / L,95%CI -10.7-0.5,P?= 0.082),但在化疗后6个月内最高6个月(10.9?Nmol / L. ,95%CI 5.5-16.4,p?<〜0.001)与化疗预疗法相比。在没有癌症的女性中,在整个研究中,25(OH)D3水平保持稳定。在化疗后,使用膳食补充剂未解释25(OH)D3水平的回收率。我们报道了乳腺癌患者的低25(OH)D3水平,在化疗期间减少,但在化疗后6个月内没有癌症观察到的女性中观察到的水平。大多数参与者的25(OH)D3水平突出了在这种脆弱人群中监测的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号